Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice

Journal of Clinical Investigation

Volumn 116, Issue 1, 2006, Pages 59-69

  Gough, Peter J ^a,b   Gomez, Ivan G ^a   Wille, Paul T ^a   Raines, Elaine W ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; ELASTIN; GELATINASE B; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME RELEASE; EXTRACELLULAR MATRIX; FEMALE; GENE OVEREXPRESSION; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; KNOCKOUT MOUSE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; COLLAGENASES; CROSSES, GENETIC; FEMALE; MACROPHAGES; MATRIX METALLOPROTEINASE 12; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 9; METALLOENDOPEPTIDASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT;

EID: 31044446194     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI25074     Document Type: Article

References (69)

1. Libby, P. 2001. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 104:365-372.
2. Libby, P., and Aikawa, M. 2002. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat. Med. 8:1257-1262.
3. Falk, E., Shah, P.K., and Fuster, V. 1995. Coronary plaque disruption. Circulation. 92:657-671.
4. Davies, M.J. 1995. Acute coronary thrombosis-the role of plaque disruption and its initiation and prevention. Eur. Heart J. 16(Suppl. L):3-7.
5. Falk, E. 1992. Why do plaques rupture? Circulation. 86:III30-42.
6. Libby, P. 1998. The interface of atherosclerosis and thrombosis: basic mechanisms. Vasc. Med. 3:225-229.
7. Zhou, J., Chew, M., Ravn, H.B., and Falk, E. 1999. Plaque pathology and coronary thrombosis in the pathogenesis of acute coronary syndromes. Scand. J. Clin. Lab. Invest. Suppl. 230:3-11.
8. Brown, D.L., Hibbs, M.S., Kearney, M., Loushin, C., and Isner, J.M. 1995. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation. 91:2125-2131.
9. Galis, Z.S., Sukhova, G.K., Lark, M.W., and Libby, P. 1994. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94:2493-2503.
10. Halpert, I., et al. 1996. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc. Natl. Acad. Sci. U. S. A. 93:9748-9753.
11. Henney, A.M., et al. 1991. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc. Natl. Acad. Sci. U. S. A. 88:8154-8158.
12. Herman, M.P., et al. 2001. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation. 104:1899-1904.
13. Li, Z., et al. 1996. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am. J. Pathol. 148:121-128.
14. Matsumoto, S., et al. 1998. Expression and localization of matrix metalloproteinase-12 in the aorta of cholesterol-fed rabbits: relationship to lesion development. Am. J. Pathol. 153:109-119.
15. Nikkari, S.T., et al. 1995. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation. 92:1393-1398.
16. Sukhova, G.K., Shi, G.P., Simon, D.I., Chapman, H.A., and Libby, P. 1998. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J. Clin. Invest. 102:576-583.
17. Sukhova, G.K., et al. 1999. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation. 99:2503-2509.
18. Blankenberg, S., et al. 2003. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 107:1579-1585.
19. Loftus, I.M., et al. 2000. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke. 31:40-47.
20. Pollanen, P.J., et al. 2001. Coronary artery complicated lesion area is related to functional polymorphism of matrix metalloproteinase 9 gene: an autopsy study. Arterioscler. Thromb. Vasc. Biol. 21:1446-1450.
21. Zhang, B., et al. 1999. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. 99:1788-1794.
22. Calara, F., et al. 2001. Spontaneous plaque rupture and secondary thrombosis in apolipoprotein Edeficient and LDL receptor-deficient mice. J. Pathol. 195:257-263.
23. Rosenfeld, M.E., et al. 2000. Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse. Arterioscler. Thromb. Vasc. Biol. 20:2587-2592.
24. Williams, H., Johnson, J.L., Carson, K.G., and Jackson, C.L. 2002. Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. Arterioscler. Thromb. Vasc. Biol. 22:788-792.
25. Johnson, J., et al. 2005. Plaque rupture after short periods of fat feeding in the apolipoprotein Eknockout mouse: model characterization and effects of pravastatin treatment. Circulation. 111:1422-1430.
26. Johnson, J.L., and Jackson, C.L. 2001. Atherosclerotic plaque rupture in the apolipoprotein E knockout mouse. Atherosclerosis. 154:399-406.
27. Zhou, X., Paulsson, G., Stemme, S., and Hansson, G.K. 1998. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J. Clin. Invest. 101:1717-1725.
28. Robertson, A.K., Zhou, X., Strandvik, B., and Hansson, G.K. 2004. Severe hypercholesterolaemia leads to strong Th2 responses to an exogenous antigen. Scand. J. Immunol. 59:285-293.
29. Gough, P.J., and Raines, E.W. 2003. Gene therapy of apolipoprotein E-deficient mice using a novel macrophage-specific retroviral vector. Blood. 101:485-491.
30. Schiller, N.K., Kubo, N., Boisvert, W.A., and Curtiss, L.K. 2001. Effect of gamma-irradiation and bone marrow transplantation on atherosclerosis in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 21:1674-1680.
31. Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J., and Glass, C.K. 1998. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 391:79-82.
32. Saarialho-Kere, U.K., Welgus, H.G., and Parks, W.C. 1993. Distinct mechanisms regulate interstitial collagenase and 92-kDa gelatinase expression in human monocytic-like cells exposed to bacterial endotoxin. J. Biol. Chem. 268:17354-17361.
33. Longo, G.M., et al. 2002. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J. Clin. Invest. 110:625-632. doi:10.1172/JCI200215334.
34. Pyo, R., et al. 2000. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J. Clin. Invest. 105:1641-1649.
35. Bannikov, G.A., Karelina, T.V., Collier, I.E., Marmer, B.L., and Goldberg, G.I. 2002. Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide. J. Biol. Chem. 277:16022-16027.
36. Fisher, K.E., et al. 2002. Engineering autoactivating forms of matrix metalloproteinase-9 and expression of the active enzyme in cultured cells and transgenic mouse brain. Biochemistry. 41:8289-8297.
37. Okada, Y., et al. 1992. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J. Biol. Chem. 267:21712-21719.
38. Carstairs, K.C. 1965. The identification of platelets and platelet antigens in histological sections. J. Pathol. Bacteriol. 90:225-231.
39. Guo, J., et al. 2005. Repopulation of apolipoprotein E knockout mice with CCR2-deficient bone marrow progenitor cells does not inhibit ongoing atherosclerotic lesion development. Arterioscler. Thromb. Vasc. Biol. 25:1014-1019.
40. Bursill, C.A., Channon, K.M., and Greaves, D.R. 2004. The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics. Curr. Opin. Lipidol. 15:145-149.
41. Boring, L., Gosling, J., Cleary, M., and Charo, I.F. 1998. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 394:894-897.
42. Boisvert, W.A., Santiago, R., Curtiss, L.K., and Terkeltaub, R.A. 1998. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J. Clin. Invest. 101:353-363.
43. Lesnik, P., Haskell, C.A., and Charo, I.F. 2003. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J. Clin. Invest. 111:333-340. doi:10.1172/JCI200315555.
44. Virmani, R., Kolodgie, F.D., Burke, A.P., Farb, A., and Schwartz, S.M. 2000. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 20:1262-1275.
45. Johnson, J.L., George, S.J., Newby, A.C., and Jackson, C.L. 2005. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc. Natl. Acad. Sci. U. S. A. 102:15575-15580.
46. Luttun, A., et al. 2004. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation. 109:1408-1414.
47. Van den Steen, P.E., Proost, P., Wuyts, A., Van Damme, J., and Opdenakker, G. 2000. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood. 96:2673-2681.
48. Heissig, B., et al. 2002. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 109:625-637.
49. Morishige, K., et al. 2003. Overexpression of matrix metalloproteinase-9 promotes intravascular thrombus formation in porcine coronary arteries in vivo. Cardiovasc. Res. 57:572-585.
50. Welgus, H.G., et al. 1990. Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development. J. Clin. Invest. 86:1496-1502.
51. Wilhelm, S.M., et al. 1989. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J. Biol. Chem. 264:17213-17221.
52. Dreier, R., Grassel, S., Fuchs, S., Schaumburger, J., and Bruckner, P. 2004. Pro-MMP-9 is a specific macrophage product and is activated by osteoarthritic chondrocytes via MMP-3 or a MT1-MMP/ MMP-13 cascade. Exp. Cell Res. 297:303-312.
53. Descamps, F.J., Martens, E., Ballaux, F., Geboes, K., and Opdenakker, G. 2004. In vivo activation of gelatinase B/MMP-9 by trypsin in acute pancreatitis is a permissive factor in streptozotocin-induced diabetes. J. Pathol. 204:555-561.
54. Carmeliet, P., et al. 1997. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat. Genet. 17:439-444.
55. Heymans, S., et al. 1999. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat. Med. 5:1135-1142.
56. Ramos-DeSimone, N., et al. 1999. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J. Biol. Chem. 274:13066-13076.
57. Fu, X., Kassim, S.Y., Parks, W.C., and Heinecke, J.W. 2001. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J. Biol. Chem. 276:41279-41287.
58. Gu, Z., et al. 2002. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science. 297:1186-1190.
59. Rajagopalan, S., Meng, X.P., Ramasamy, S., Harrison, D.G., and Galis, Z.S. 1996. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J. Clin. Invest. 98:2572-2579.
60. Hazen, S.L. 2004. Myeloperoxidase and plaque vulnerability. Arterioscler. Thromb. Vasc. Biol. 24:1143-1146.
61. Brennan, M.L., and Hazen, S.L. 2003. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr. Opin. Lipidol. 14:353-359.
62. Brennan, M.L., et al. 2001. Increased atherosclerosis in myeloperoxidase-deficient mice. J. Clin. Invest. 107:419-430.
63. Fingleton, B. 2003. Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects. Expert Opin. Ther. Targets. 7:385-397.
64. Garton, K.J., Ferri, N., and Raines, E.W. 2002. Efficient expression of exogenous genes in primary vascular cells using IRES-based retroviral vectors. Biotechniques. 32:830, 832, 834, passim.
65. Gough, P.J., et al. 2004. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J. Immunol. 172:3678-3685.
66. Kozaki, K., et al. 2002. Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in ApoE null mice. Am. J. Pathol. 161:1395-1407.
67. Mach, F., Schonbeck, U., Sukhova, G.K., Atkinson, E., and Libby, P. 1998. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 394:200-203.
68. Ferri, N., Garton, K.J., and Raines, E.W. 2003. An NF-kappaB-dependent transcriptional program is required for collagen remodeling by human smooth muscle cells. J. Biol. Chem. 278:19757-19764.
69. Shipley, J.M., Wesselschmidt, R.L., Kobayashi, D.K., Ley, T.J., and Shapiro, S.D. 1996. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc. Natl. Acad. Sci. U. S. A. 93:3942-3946.